Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Crossover Experiments01:16

Crossover Experiments

Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and tolerability of low versus standard daily doses of antiseizure medications in newly diagnosed focal epilepsy. A multicenter, randomized, single-blind, non-inferiority trial (STANDLOW).

Epilepsia open·2025
Same author

Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX).

Scientific reports·2025
Same author

Retraction notice to "Neurological outcome of post-anoxic refractory status epilepticus after aggressive treatment" [Epilepsy Behav. 101 (2019) 106374].

Epilepsy & behavior : E&B·2024
Same author

Risk factors for attempted suicide in non-psychotic patients with suicidal ideation.

Rivista di psichiatria·2024
Same author

Prevalence of epilepsy in childhood: An epidemiological study in Sardinia.

Epilepsy & behavior : E&B·2023
Same author

Pitfalls and biases in neuroepidemiological studies of COVID-19 and the nervous system: a critical appraisal of the current evidence and future directions.

Journal of neurology·2023

Related Experiment Video

Updated: May 19, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Randomised controlled monotherapy trials: which comparators to use?

Ettore Beghi1

  • 1Laboratorio di Malattie Neurologiche, Dipartimento di Neuroscienze, Istituto Mario Negri, Milano, Italy.

Epileptic Disorders : International Epilepsy Journal with Videotape
|September 4, 2012
PubMed
Summary
This summary is machine-generated.

Selecting the first-choice epilepsy drug is critical, as newer options offer similar efficacy to older ones but with varied side effect profiles. Carbamazepine and ethosuximide remain preferred for partial and absence epilepsy, respectively, with no clear alternative for generalized epilepsies.

More Related Videos

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Related Experiment Videos

Last Updated: May 19, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Epilepsy monotherapy is effective for about 50% of newly diagnosed patients.
  • First- and second-generation antiepileptic drugs (AEDs) show similar efficacy but differ in pharmacokinetics, tolerability, and safety.
  • No single AED possesses an ideal profile, and newer drugs lack clear advantages over older ones.

Purpose of the Study:

  • To evaluate the critical selection of first-choice drugs for epilepsy monotherapy trials.
  • To analyze the efficacy, tolerability, and safety profiles of existing AEDs.
  • To identify optimal comparators for new monotherapy clinical trials.

Main Methods:

  • Review of existing evidence-based guidelines and clinical trial data.
  • Comparative analysis of pharmacokinetic, tolerability, and safety profiles of first- and second-generation AEDs.
  • Assessment of AED efficacy in different epilepsy types (partial, absence, generalized).

Main Results:

  • Carbamazepine is recommended for partial epilepsy, and ethosuximide for absence epilepsy.
  • Newer AEDs offer similar efficacy to older ones, with potentially fewer idiosyncratic reactions and drug interactions.
  • No preferred drug is clearly indicated for generalized epilepsies, especially considering valproate's teratogenicity in women of childbearing age.

Conclusions:

  • Standard criteria for selecting comparator drugs in epilepsy monotherapy trials are lacking.
  • Evidence-based guidelines support carbamazepine and ethosuximide for specific epilepsy types.
  • Further research is needed to identify effective and safe alternatives for generalized epilepsies, particularly for women of childbearing potential.